Numbing condoms could be a Game-Changer for quick ejaculation
NCT ID NCT05840172
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether condoms containing a mild numbing agent (benzocaine) help men who feel they ejaculate too quickly last longer during vaginal sex. Three hundred healthy adult men in stable relationships tried two types of medicated condoms and one regular condom, recording how long they lasted each time. The goal was to see if the numbing condoms increased time to ejaculation compared to standard condoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
300 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Oct 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Main Inclusion Criteria: 1. Subjects and their female partners have provided written informed consent. 2. Subjects and their female partners between the ages of \>= 18 years and =\< 60 years. 3. Subjects and their female partners must have no health condition in their medical history. 4. Subject must be sexually active having regular intercourse. 5. Subjects in a stable, monogamous, sexual relationship with the same female partner for more than or equal to 3 months. 6. Subject's female partner should already be on an established other highly effective form of non-barrier contraception, unless post-menopausal. 7. Subjects reporting a frequency of 'occasionally' to the Sexual Intercourse Self-Estimation Scale. Main Exclusion Criteria: 1. Subject with a pregnant or breastfeeding female partner or the female partner desires to become pregnant during the clinical investigation. 2. Subject or his female partner with a current history of alcohol or drug abuse. 3. Subjects and their female partners with a history of or are suffering from anemia, coronary artery disease, impaired cardiac conduction, pulmonary disease, diabetes, and renal or hepatic disease. 4. Subjects and their female partners with a history of, suspected to have, or be at increased risk of methaemoglobinemia / complications related to ester anaesthetics which could trigger methemoglobinemia. 5. Subject and/or his female partner have a physical or psychological condition that would prevent them from following investigation procedures - including but not limited to the following: 1. urological disease, 2. ongoing significant psychiatric disorder not controlled by medication 3. history of surgery or injury to the pelvis, retroperitoneal surgery, radiotherapy, multiple sclerosis, spinal cord injury, chronic inflammation of the prostate or urethra 4. relevant previous or planned genital surgery 5. female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness) 6. any broken skin or wounds in the genital area. 6. Subjects on medication that is contraindicated, which may affect erection. 7. Subject and/or his female partner have any medication which may affect the safety of the subject, including but not limited to benzocaine drug interactions such as cholinesterase inhibitors. 8. Subject and/or his female partner is using or intends to continue to use antibiotics of the sulphonamide type. 9. Subject with premature ejaculation, erectile dysfunction, hypo or hyperthyroidism, hypogonadism, hyperprolactinemia, ejaculatory dysfunction, haemorrhagic disorder, hepatitis B or C, human immunodeficiency virus (HIV) infection or having had penile implant surgery. 10. Subject that has been diagnosed or received treatment for PE (premature ejaculation). 11. Subjects with confirmed erectile dysfunction, hypo or hyperthyroidism, hypogonadism, hyperprolactinemia. 12. Confirmed diagnosis of male subjects with other forms of ejaculatory dysfunction. 13. Subjects that have had prior genital, prostatic or lower tract surgery. 14. Subjects with haemorrhagic disorder, hepatitis B or C, HIV infection or having had penile implant surgery, at any time in their past. 15. Either partner needed to use condoms for a specific STI protection. 16. Subjects and their female partners who have any relevant history of allergy including local anaesthetics, parabens, PABA, commercial hair dyes, paraphenylenediamine, lubricants and latex.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ejaculation delayed are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SGS proderm GmbH
Hamburg, Germany